Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-01-28

NANO-X IMAGING LTD

Nanox develops digital tomosynthesis imaging systems and sells attached teleradiology and imaging-AI software services to healthcare providers.

ai healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

From device pilots to recurring radiology utility

A credible shift to utilization-linked recurring contracts could re-rate the business toward medtech services peers by 2031. The key risks are dilution, service reliability, and converting deployments into sustained paid volume.

Analysis

Thesis

If Nanox converts deployments into repeatable utilization-linked contracts (imaging + workflow + interpretation + AI add-ons), it can compound from small revenue to a mid-scale recurring services profile and earn a peer-like medtech/services multiple; the key gates are financing, uptime, and adoption proof.

Last Economy Alignment

Radiology interpretation and workflow are getting automated; value shifts to distribution, trust, and verified pipelines. Nanox is positioned to bundle device + cloud + reading capacity, but lacks scaled proof and must fund the ramp.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

6.7x (from 5 most recent analyses)

Reasoning

The non-linear upside is a business-model shift: recurring per-study economics (reads + workflow + AI) can scale faster than hardware placements and be valued closer to services/software peers. If Nanox proves repeatable go-lives, reliable performance, and rising recurring mix, a ~peer-range sales multiple on materially higher revenue implies a high-single-digit uplift versus today despite expected dilution along the way.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

Nanox’s outcome is gated by (1) funding the ramp without excessive dilution, (2) proving repeatable deployments with high uptime and clinician acceptance, and (3) demonstrating attractive per-study economics so recurring revenue scales faster than costs. Any sustained miss on deployment/utilization milestones can trigger a negative loop: weaker confidence → higher cost of capital → slower scale.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new earnings release or updated guidance observed in the past 7–10 days; last major operating update remains the Nov 20, 2025 quarterly release.
No new regulatory disclosures observed in the past 7–10 days; attention remains on follow-on software/module clearance timelines.
Near-term investor focus remains on financing/dilution optics and confirmation of year-end deployment progress.

Forecast update

Higher confidence in a peer-multiple outcome if 2026 guidance is hit and recurring mix grows; still gated by financing and repeatability proof.

Upgrade to Builder to also access: Future Considerations

Third Party Analyst Consensus

12-Month Price Target

$8.15

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case